IP Library Granted Patent US 10,648,971
Granted Patent B2
US 10,648,971 · App. 16/035,117 · Granted May 12, 2020

Activation of bioluminescence by structural complementation

Inventors: Andrew S. Dixon (Verona, WI); Lance Encell (Fitchburg, WI); Mary Hall (Waunakee, WI); Keith Wood (Mt. Horeb, WI); Monika Wood (Mt. Horeb, WI); Marie Schwinn (Madison, WI); Brock F. Binkowski (Sauk City, WI); Hicham Zegzouti (Madison, WI); Nidhi Nath (Madison, WI); Subhanjan Mondal (Middleton, WI); Said Goueli (Fitchburg, WI); Poncho Meisenheimer (San Luis Obispo, CA); Thomas Kirkland (Atascadero, CA); James Unch (Arroyo Grande, CA); Dileep K. Pulukkunat (Middleton, WI); Matthew Robers (Madison, WI); Melanie Dart (Madison, WI); Thomas Machleidt (Madison, WI)
Assignee: Promega Corporation
G01N33/533A61K51/08C07K7/08C07K14/43509C12N9/0069C12Q1/66G01N33/542G01N33/581
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,648,971
App. No.
16/035,117
Granted
May 12, 2020
Kind
B2
Abstract

Provided herein are compositions and methods for the assembly of a bioluminescent complex from two or more non-luminescent (e.g., substantially non-luminescent) peptide and/or polypeptide units. In particular, bioluminescent activity is conferred upon a non-luminescent polypeptide via structural complementation with another, complementary non-luminescent peptide.

Claims (15)

1. A peptide comprising an amino acid sequence having greater than 70% sequence identity with SEQ ID NO: 390 or SEQ ID NO: 2271, but less than 100% sequence identify with SEQ ID NO: 2, wherein a bioluminescent signal produced in the presence of a furimazine substrate is increased when the peptide contacts a polypeptide consisting of SEQ ID NO: 440 when compared to a bioluminescent signal produced by the peptide and furimazine substrate alone, and wherein the amino acid sequence of the peptide is not a naturally occurring protein or a fragment thereof.

2. The peptide of claim 1 , wherein the bioluminescent signal is substantially increased when the peptide associates with the polypeptide consisting of SEQ ID NO: 440.

3. The peptide of claim 1 , wherein the peptide exhibits enhancement of one or more traits compared to a peptide of SEQ ID NO: 2, wherein the traits are selected from: affinity for the polypeptide consisting of SEQ ID NO: 440, expression, intracellular solubility, intracellular stability, and bioluminescent activity when combined with the polypeptide consisting of SEQ ID NO: 440.

4. The peptide of claim 1 , wherein the amino acid sequence is synthetic, contains non-natural amino acids or is a peptide mimic.

5. A bioluminescent complex comprising:

(a) the peptide of claim 1 ; and

(b) a polypeptide comprising an amino acid sequence having greater than 40% but less than 100% sequence identity with SEQ ID NO: 440;

wherein a bioluminescent signal produced by the bioluminescent complex in the presence of a furimazine substrate is substantially increased when compared to a bioluminescent signal produced in the presence of furimazine substrate by the peptide or the polypeptide alone.

6. A fusion polypeptide comprising the peptide of claim 1 and a first interaction polypeptide that is configured to form a complex with a second interaction polypeptide upon contact of the first interaction polypeptide and the second interaction polypeptide.

7. A bioluminescent complex comprising:

(a) the fusion polypeptide of claim 6 ; and

(b) a second fusion polypeptide comprising:

(i) the second interaction polypeptide, and

(ii) a complement a polypeptide comprising an amino acid sequence having greater than 40% but less than 100% sequence identity with SEQ ID NO: 440;

wherein a bioluminescent signal produced by the bioluminescent complex in the presence of a furimazine substrate is substantially increased when compared to a bioluminescent signal produced in the presence of furimazine substrate by the peptide or the polypeptide alone.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2018
From: DIXON, ANDREW S.; ENCELL, LANCE; HALL, MARY; WOOD, KEITH; WOOD, MONIKA; SCHWINN, MARIE; BINKOWSKI, BROCK F.; ZEGZOUTI, HICHAM; NATH, NIDHI; MONDAL, SUBHANJAN; GOUELI, SAID; MEISENHEIMER, PONCHO; KIRKLAND, THOMAS; UNCH, JAMES; PULUKKUNAT, DILEEP K.; ROBERS, MATTHEW; DART, MELANIE; MACHLEIDT, THOMAS
To: PROMEGA CORPORATION
Reel/Frame 046875/0174 →
Continuity (6)
Continuation 16023972 · Jun 29, 2018
Continuation 15717534 · Sep 27, 2017
Continuation 15073249 · Mar 17, 2016
Continuation 14209610 · Mar 13, 2014
Provisional Application 61791549 · Mar 15, 2013
Related Publication 20180313825A1 · Nov 1, 2018
Cited By (2)
US 12,366,572 US 12,367,513